Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 11,330 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cohorting Clear all
Not listed No phase listed Observational

Hospital-wide Incidence, Clinical Characteristics and Outcomes of ARDS

NCT03546699
View directory record Official record
Conditions
ARDS, Respiratory Failure, Lung Ultrasound
Interventions
Estimation of hospital-wide incidence of ARDS
Diagnostic Test
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years and older
Enrollment
9,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Oct 20, 2026, 1:45 AM EDT
Active, not recruiting No phase listed Observational

Effects of Transitional Circulation in ELBW Infants

NCT02016599
View directory record Official record
Conditions
Neonatal Prematurity, Hypotension
Interventions
Monitoring and biospecimen collection
Other
Lead sponsor
University of Iowa
Other
Eligibility
Up to 1 Week
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 20, 2026, 1:45 AM EDT
Active, not recruiting Phase 2 Interventional

TReatment for ImmUne Mediated PathopHysiology

NCT04862221
View directory record Official record
Conditions
Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Interventions
High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone, Placebo for prednisolone, Placebo for infusions, Diphenhydramine, Methylprednisolone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
1 Year to 18 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 20, 2026, 1:45 AM EDT
Completed No phase listed Observational

Preventing Cardiac Sequelae in Pediatric Cancer Survivors

NCT01805778
View directory record Official record
Conditions
Anthracycline-induced Cardiotoxicity
Interventions
Not listed
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
Up to 18 Years
Enrollment
1,128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Oct 20, 2026, 1:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA

NCT02113163
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent, Hypertriglyceridemia
Interventions
Metformin Eicosapentaenoate, Metformin HCl and Vascepa
Drug
Lead sponsor
Thetis Pharmaceuticals LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 20, 2026, 1:45 AM EDT
Recruiting Not applicable Interventional

NEPTUNE Match Study

NCT04571658
View directory record Official record
Conditions
Nephrotic Syndrome in Children, Focal Segmental Glomerulosclerosis, Minimal Change Disease, Minimal Change Nephrotic Syndrome, Membranous Nephropathy, FSGS, MCD, MCD - Minimal Change Disease, Alport Syndrome
Interventions
Communication
Other
Lead sponsor
University of Michigan
Other
Eligibility
1 Year to 80 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
16
States / cities
Atlanta, Georgia • Chicago, Illinois • Kansas City, Kansas + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 20, 2026, 1:45 AM EDT
Terminated Phase 1 Interventional

Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors

NCT00796055
View directory record Official record
Conditions
Cancer
Interventions
MEDI-547
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 20, 2026, 1:45 AM EDT
Not yet recruiting No phase listed Observational

Outcomes Registry After Ketamine Infusions for Chronic Pain: A Longitudinal Evaluation

NCT07648771
View directory record Official record
Conditions
Chronic Pain, Ketamine
Interventions
Ketamine (Ketalar)
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 20, 2026, 1:45 AM EDT
Completed Not applicable Interventional Results available

Long Duration Activity and Metabolic Control After Spinal Cord Injury

NCT03139344
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Low-frequency Exercise, High-frequency Exercise
Other
Lead sponsor
Richard K Shields
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 20, 2026, 1:45 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 in Adult Subjects With Hereditary Angioedema

NCT06846398
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
BW-20805
Drug
Lead sponsor
Shanghai Argo Biopharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Silver Spring, Maryland • St Louis, Missouri • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 20, 2026, 1:45 AM EDT
Not listed Phase 1Phase 2 Interventional

The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19

NCT04798716
View directory record Official record
Conditions
Covid19, Novel Coronavirus Pneumonia, Acute Respiratory Distress Syndrome
Interventions
MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8), MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8), MSC-exosomes delivered intravenously every other day (8:8:8)
Drug
Lead sponsor
AVEM HealthCare
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Panorama City, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 20, 2026, 1:45 AM EDT
Completed No phase listed Observational

Measuring Outcomes With Validated Exercise

NCT07270185
View directory record Official record
Conditions
Physical Activity
Interventions
Not listed
Lead sponsor
Boston University
Other
Eligibility
18 Years to 89 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 20, 2026, 1:45 AM EDT
Completed Not applicable Interventional

Heterosexual HIV Transmission Study (HATS). Prospective Cohort Study

NCT00000787
View directory record Official record
Conditions
HIV Infections
Interventions
Pre- and post-test counseling
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 1:45 AM EDT
Active, not recruiting Phase 1 Interventional

Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib

NCT03422393
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Venetoclax, Ibrutinib
Drug
Lead sponsor
Michael Choi
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 20, 2026, 1:45 AM EDT
Withdrawn No phase listed Observational

Post-Breast Procedure Pain Syndrome Study

NCT01114984
View directory record Official record
Conditions
Breast, Mastectomy, Segmental
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2015 · Synced Oct 20, 2026, 1:45 AM EDT
Completed Phase 2 Interventional Results available

A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

NCT04701658
View directory record Official record
Conditions
COVID-19
Interventions
Bamlanivimab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 20, 2026, 1:45 AM EDT
Completed Phase 1 Interventional

A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

NCT01193478
View directory record Official record
Conditions
HCV Infection
Interventions
GS-5885, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
13
States / cities
Anaheim, California • Cypress, California • National City, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2013 · Synced Oct 20, 2026, 1:45 AM EDT
Completed No phase listed Observational Results available

Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing

NCT03932799
View directory record Official record
Conditions
Opioid Use, Opioid-Related Disorders
Interventions
Prospective prior authorization (PA) with hard stops in Washington, Retrospective review (RR) with prescriber notification in Ohio
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
5,411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Columbus, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 20, 2026, 1:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2484595 in Healthy Subjects

NCT01450098
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY2484595 Reference Formulation (RF), LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 20, 2026, 1:45 AM EDT
Recruiting Phase 1Phase 2 Interventional

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

NCT05482893
View directory record Official record
Conditions
Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC), Colorectal Cancer
Interventions
Spevatamig (PT886), Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab), FOLFOX, CAPOX, FOLFIRINOX, TAS 102, Bevacizumab, Gemcitabine Combined With Cisplatin, NALIRIFOX
Drug
Lead sponsor
Phanes Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
11
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 20, 2026, 1:45 AM EDT
Active, not recruiting Not applicable Interventional

PA Moves Trial - PCP Participants

NCT05319821
View directory record Official record
Conditions
Behavior, Physical Activity
Interventions
Receive ECHO training, Offered ECHO training in year 5
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
Hershey, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 20, 2026, 1:45 AM EDT
Completed No phase listed Observational

Mechanomyography for Predictor of Prognosis in CuTS and PND Patients

NCT04322448
View directory record Official record
Conditions
Cubital Tunnel Syndrome, Peroneal Nerve Entrapment
Interventions
Mechanomyography (MMG)
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Rochester, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 20, 2026, 1:45 AM EDT
Completed Phase 1 Interventional

Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

NCT05309187
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
IO-202, IO-202 + pembrolizumab combination therapy, RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types
Biological
Lead sponsor
Immune-Onc Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Los Angeles, California • Gainesville, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 20, 2026, 1:45 AM EDT
Recruiting Phase 1 Interventional

Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis

NCT06201416
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SBT777101
Biological
Lead sponsor
Sonoma Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
Scottsdale, Arizona • San Francisco, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 20, 2026, 1:45 AM EDT